NC-TCSP-IRMf: Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder

Sponsor
University Hospital, Clermont-Ferrand (Other)
Overall Status
Unknown status
CT.gov ID
NCT03425214
Collaborator
CH MONTLUCON (Other), Jacques Lacarin Hospital Center (Other)
66
1
3
17.3
3.8

Study Details

Study Description

Brief Summary

Up to 50% of Narcolepsy-cataplexy (NC) patients suffer from REM sleep behavior disorder (RBD), a parasomnia.

A strong link was found between RBD and impulse control disorders (ICD) in Parkinson disease (PD) patients. ICD are thought to be related to a dysfunction of meso-cortico-limbic pathways which belong to the so called ''reward system''.

A recent study in IRMf shows that RBD is associated with impaired reward system.

A strong link was found between these two disorders and therefore we believe that RBD is associated with impaired reward system in NC

The main objective of this study is to evaluate differences in brain activation between NC patients with and without RBD.

The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.

Condition or Disease Intervention/Treatment Phase
  • Other: fMRI
  • Other: Videopolysomnography
  • Other: NC (narcolepsy-cataplexy)
N/A

Detailed Description

Type of study: Prospective, case control study.

Number of centers: 3 (Clermont-Ferrand, Vichy and Montlucon)

Patients :

The study will be performed in 66 subjects (22 PD patients with RBD, 22 PD patients without RBD and 22 healthy volunteers, age-and sex-matched without any contraindications to perform an MRI)

Study Performance :

During the first visit (Baseline, inclusion visit, 2 hours), each subject will perform a clinical and neurological examination and neuropsychological assessment (depression by the Beck Depression Inventory (BDI); apathy by the Lille Apathy Rating Scale (LARS), impulsivity by the Urgency, lack of Premeditation, lack of Perseverance, Sensation Seeking scale (UPPS)) Eligible patients will be welcomed for a video Polysomnography in the sleep center, for one night (Month 1, 1 night) and in a subsequent visit at the MRI department for the functional MRI (Month 1, 1 hour). This session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is the"monetary incentive delay task".

Study Design

Study Type:
Interventional
Anticipated Enrollment :
66 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder
Actual Study Start Date :
Jan 19, 2018
Anticipated Primary Completion Date :
Jun 30, 2019
Anticipated Study Completion Date :
Jun 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: NC with RBD

fMRI and video polysmnography

Other: fMRI
Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is the"monetary incentive delay task".

Other: Videopolysomnography
Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.

Experimental: NC without RBD

fMRI and video polysomnography

Other: NC (narcolepsy-cataplexy)
The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.

Experimental: control group (healthy subjects)

fMRI

Other: fMRI
Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is the"monetary incentive delay task".

Outcome Measures

Primary Outcome Measures

  1. Measure of BOLD signal variation in each region of interest [at Month 1]

    BOLD signal variation in each region of interest (ventral tegmental area, accumbens nucleus, limbic cortex, prefrontal cortex) measured during fMRI

Secondary Outcome Measures

  1. reaction time to the task [at Month 1]

  2. performance score to the task [at Month 1]

  3. Beck Depression Inventory score measured during fMRI [at baseline]

  4. Lille Apathy Rating Scale score measured during fMRI [at baseline]

  5. impulsivity score by the Urgency measured during fMRI [at baseline]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
    • Men or women, right handed, 18 to 80 years
  • Patients with type 1 Narcolepsy according to the criteria of the International Classification of Sleep, 3rd version, 2014

  • Acceptance of the protocol and signature of a written consent

  • Social security affiliation

Exclusion Criteria:
  • Previous history of psychosis or psychiatric disease

  • History of stroke or vascular lesion on MRI.

  • Perceptual disorder (vision, hearing) may hinder the realization of the protocols,

  • Dementia defined by a score across Montreal Cognitive Assessment (MoCA) <26/30.

  • Major depressive state defined by a score scale Beck Depression Inventory (BDI)> 14

  • Apathy defined by a score ≥ 14 on the Apathy Scale of Starkstein. Patients with a score ≥ this one will be excluded.

  • Usual contraindications to MRI, knowing that no contrast agent injection is performed.

  • Pregnant woman.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Clermont-Ferrand Clermont-Ferrand France 63003

Sponsors and Collaborators

  • University Hospital, Clermont-Ferrand
  • CH MONTLUCON
  • Jacques Lacarin Hospital Center

Investigators

  • Principal Investigator: Maria-Livia FANTINI, University Hospital, Clermont-Ferrand

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT03425214
Other Study ID Numbers:
  • CHU-375
  • 2017-A01974-49
First Posted:
Feb 7, 2018
Last Update Posted:
Feb 9, 2018
Last Verified:
Feb 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Clermont-Ferrand
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2018